{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T01:51:24Z","timestamp":1791165084427,"version":"4.1.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.parkreldis.2011.10.021","type":"journal-article","created":{"date-parts":[[2011,12,16]],"date-time":"2011-12-16T01:50:34Z","timestamp":1324000234000},"page":"316-320","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["An evidence-based approach in the treatment of Huntington\u2019s disease"],"prefix":"10.1016","volume":"18","author":[{"given":"T.A.","family":"Mestre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2011.10.021_bib1","unstructured":"European Medicines Agency E. Orphan designation. 2011 [cited 2011 4th February]; Available from: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/regulation\/general\/general_content_000029.jsp&murl=menus\/regulations\/regulations.jsp&mid=WC0b01ac05800240ce&jsenabled=true"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib2","unstructured":"Clinicaltrials.gov. 2010; Available from: http:\/\/clinicaltrials.gov\/ct2\/results?term=Huntington%27s+disease&cond=%22Huntington+Disease%22."},{"key":"10.1016\/j.parkreldis.2011.10.021_bib3","first-page":"CD006456","article-title":"Therapeutic interventions for symptomatic treatment in Huntington\u2019s disease","author":"Mestre","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib4","first-page":"CD006455","article-title":"Therapeutic interventions for disease progression in Huntington\u2019s disease","author":"Mestre","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib5","series-title":"Public summary of opinion on orphan designation: Lithium citrate tetrahydrate (in reverse-micelle formulation) for the treatment of Huntington\u2019s disease","author":"European Medicines Agency E","year":"2011"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib6","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2147\/NDT.S6430","article-title":"Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease","volume":"6","author":"Frank","year":"2010","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib7","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0006-8993(95)00674-F","article-title":"Regional distribution of monoamine vesicular uptake sites in the mesencephalon of control subjects and patients with Parkinson\u2019s disease: a postmortem study using tritiated tetrabenazine","volume":"692","author":"Thibaut","year":"1995","journal-title":"Brain Res"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib8","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0014-2999(84)90562-4","article-title":"Tetrabenazine-induced depletion of brain monoamines: characterization and interaction with selected antidepressants","volume":"102","author":"Pettibone","year":"1984","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib9","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","article-title":"Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial","volume":"66","author":"HSG","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib10","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1471-2377-9-62","article-title":"Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group\/TETRA-HD Investigators","volume":"9","author":"Frank","year":"2009","journal-title":"BMC Neurol"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib11","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1136\/jnnp.47.8.844","article-title":"A\u00a0double blind trial of sulpiride in Huntington\u2019s disease and tardive dyskinesia","volume":"47","author":"Quinn","year":"1984","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib12","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1185\/03007998409109601","article-title":"Tiapride versus placebo: a double-blind comparative study in the management of Huntington\u2019s chorea","volume":"9","author":"Deroover","year":"1984","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1600-0404.1982.tb03060.x","article-title":"Tiapride in the treatment of Huntington\u2019s chorea","volume":"65","author":"Roos","year":"1982","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/jnnp.63.1.35","article-title":"Clozapine versus placebo in Huntington\u2019s disease: a double blind randomised\\ comparative study","volume":"63","author":"van Vugt","year":"1997","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib15","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1212\/WNL.59.5.694","article-title":"Huntington\u2019s disease: a randomized, controlled trial using the NMDA-antagonist amantadine","volume":"59","author":"Verhagen Metman","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib16","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/archneur.60.7.996","article-title":"A\u00a0randomized trial of amantadine in Huntington disease","volume":"60","author":"O\u2019Suilleabhain","year":"2003","journal-title":"Arch Neurol"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib17","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1212\/01.WNL.0000096019.71649.2B","article-title":"Dosage effects of riluzole in Huntington\u2019s disease: a multicenter placebo-controlled study","volume":"61","author":"group HS","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib18","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/ana.21181","article-title":"Riluzole in Huntington\u2019s disease: a 3-year, randomized controlled study","volume":"62","author":"Landwehrmeyer","year":"2007","journal-title":"Ann Neurol"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib19","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/0091-3057(91)90386-G","article-title":"Controlled clinical trial of cannabidiol in Huntington\u2019s disease","volume":"40","author":"Consroe","year":"1991","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib20","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1002\/mds.22809","article-title":"A\u00a0pilot study using nabilone for symptomatic treatment in Huntington\u2019s disease","volume":"24","author":"Curtis","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib21","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/mds.870120319","article-title":"A\u00a0controlled trial of fluoxetine in nondepressed patients with Huntington\u2019s disease","volume":"12","author":"Como","year":"1997","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib22","series-title":"NeuroSearch announces positive top-line results from Phase III Huntexil\u00ae study in Huntington\u2019s disease Neurosearch","author":"Pedersen","year":"2010"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib23","series-title":"The HART study with Huntexil\u00ae shows significant effect on total motor function in patients with Huntington\u2019s disease although it did not meet the primary endpoint after 12 weeks of treatment. Neurosearch","author":"Dahlen","year":"2010"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib24","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.nurt.2009.10.003","article-title":"Poster 19: Validation of the modified motor score (mMS): a Subscale of the Unified Huntington\u2019s disease rating scale (UHDRS) motor score","volume":"7","author":"Waters","year":"2010","journal-title":"Neurotherapeutics journal Am Soc for Exp NeuroTherapeutics"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib25","series-title":"NeuroSearch A\/S announces the results of additional assessment and analysis of data from the Phase III MermaiHD study with Huntexil\u00ae in Huntington\u2019s disease. Neurosearch","author":"Pedersen","year":"2010"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib26","unstructured":"Dahlen P. NeuroSearch announces the results of a meta-analysis of data from a clinical Phase II\/III programme with Huntexil\u00ae for Huntington\u2019s disease. Neurosearch; [4 February 2011]; Available from: http:\/\/www.euro-hd.net\/html\/projects\/acr16\/NeuroSearch-announcement-30.12.10.pdf."},{"key":"10.1016\/j.parkreldis.2011.10.021_bib27","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.2174\/138161206777698693","article-title":"Pharmacological management of Huntington\u2019s disease: an evidence-based review","volume":"12","author":"Bonelli","year":"2006","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib28","first-page":"219","article-title":"Behavioral changes in huntington disease","volume":"14","author":"Craufurd","year":"2001","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib29","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.biopsych.2006.11.034","article-title":"Psychiatric symptoms in Huntington\u2019s disease before diagnosis: the predict-HD study","volume":"62","author":"Duff","year":"2007","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib30","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/archneur.64.1.116","article-title":"Specific psychiatric manifestations among preclinical Huntington disease mutation carriers","volume":"64","author":"Marshall","year":"2007","journal-title":"Arch Neurol"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib31","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/jnp.2007.19.4.441","article-title":"Psychopathology in verified Huntington\u2019s disease gene carriers","volume":"19","author":"van Duijn","year":"2007","journal-title":"J\u00a0Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib32","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1136\/jnnp.2007.136895","article-title":"The nosological position of apathy in clinical practice","volume":"79","author":"Starkstein","year":"2008","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib33","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00213-008-1068-0","article-title":"The effects of modafinil on mood and cognition in Huntington\u2019s disease","volume":"199","author":"Blackwell","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib34","unstructured":"EURO-HD. 2011 [cited 2011 Jan 2011]; Available from: http:\/\/www.euro-hd.net\/html\/disease\/archive\/ehdn-newsletter-jan2011.pdf."},{"key":"10.1016\/j.parkreldis.2011.10.021_bib35","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1136\/jmg.30.4.289","article-title":"Onset symptoms in 510 patients with Huntington\u2019s disease","volume":"30","author":"Di Maio","year":"1993","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib36","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1212\/WNL.53.5.1000","article-title":"Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial","volume":"53","author":"Kremer","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib37","series-title":"Depression: the treatment and management of depression in adults","year":"2009"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib38","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s11940-010-0088-3","article-title":"Treatment of irritability in Huntington\u2019s disease","volume":"12","author":"van Duijn","year":"2010","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib39","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/01.wnl.0000238106.10423.00","article-title":"Effect of donepezil on motor and cognitive function in Huntington disease","volume":"67","author":"Cubo","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib40","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/JCP.0b013e3181b2ac0a","article-title":"Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease","volume":"29","author":"Beglinger","year":"2009","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib41","first-page":"263","article-title":"L-acetyl-carnitine in Huntington\u2019s disease: double-blind placebo controlled crossover study of drug effects on movement disorder and dementia","volume":"5","author":"Goety","year":"1990","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib42","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00001756-200201210-00029","article-title":"MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment","volume":"13","author":"Puri","year":"2002","journal-title":"Neuroreport"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib43","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1212\/01.wnl.0000169025.09670.6d","article-title":"Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial","volume":"65","author":"Puri","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib44","first-page":"1582","article-title":"Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study","volume":"65","author":"HSG","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib45","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1212\/WNL.57.3.397","article-title":"A\u00a0randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington\u2019s disease","volume":"57","author":"HSG","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib46","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/mds.870110510","article-title":"A\u00a0controlled trial of idebenone in Huntington\u2019s disease","volume":"11","author":"Ranen","year":"1996","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib47","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1212\/WNL.49.1.153","article-title":"Cognitive, behavioral, and motor effects of the NMDA antagonist ketamine in Huntington\u2019s disease","volume":"49","author":"Murman","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib48","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/mds.870110310","article-title":"A\u00a0controlled trial of remacemide hydrochloride in Huntington\u2019s disease","volume":"11","author":"Kieburtz","year":"1996","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib49","series-title":"Pilot study of memantine for cognitive and behavioral dysfunction in Huntington\u2019s disease","author":"Corey-Bloom","year":"2010"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib50","series-title":"Placebo-Controlled pilot study in Huntington\u2019s disease (CIT-HD)","author":"Randomized","year":"2010"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib51","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1001\/archneurol.2009.334","article-title":"A\u00a0randomized, placebo-controlled trial of latrepirdine in Huntington disease","volume":"67","author":"Kieburtz","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib52","series-title":"Pfizer and Medivation Announce results from phase 3 Horizon trial of Dimebon in huntington disease","author":"Medivation","year":"2011"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib53","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1176\/ajp.152.12.1771","article-title":"Trial of d-alpha-tocopherol in Huntington\u2019s disease","volume":"152","author":"Peyser","year":"1995","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib54","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/ana.410250308","article-title":"A\u00a0controlled clinical trial of baclofen as protective therapy in early Huntington\u2019s disease","volume":"25","author":"Shoulson","year":"1989","journal-title":"Ann Neurol"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib55","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/01.wnl.0000194318.74946.b6","article-title":"Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2\u2019dG","volume":"66","author":"Hersch","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib56","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1002\/mds.23236","article-title":"A\u00a0futility study of minocycline in Huntington\u2019s disease","volume":"25","year":"2010","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib57","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1474-4422(10)70276-3","article-title":"Biological and clinical changes in premanifest and early stage Huntington\u2019s disease in the TRACK-HD study: the 12-month longitudinal analysis","volume":"10","author":"Tabrizi","year":"2011","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.parkreldis.2011.10.021_bib58","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000228840","article-title":"Pharmacological treatment of apathy in neurodegenerative diseases: a systematic review","volume":"28","author":"Drijgers","year":"2009","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/j.parkreldis.2011.10.021_bib59","unstructured":"Generalised anxiety disorder and panic disorder (with or without agoraphobia) in adults. National Institute for Health and Clinical Excellence; 2011."}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802011003877?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802011003877?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:13:20Z","timestamp":1761178400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802011003877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S1353802011003877"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2011.10.021","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An evidence-based approach in the treatment of Huntington\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2011.10.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}